AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
alogliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| dipeptidyl aminopeptidase-IV inhibitors | 4340 | 850649-61-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4) that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 18 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
| fu (Fraction unbound in plasma) | 0.84 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.503 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 5.284 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 1.081 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.820 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 81.150 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 75.380 | % | High | 1 |
| herg | hERG pIC50 | 4.488 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.138 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.126 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 82.910 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PRKDC,SIK2,SIK3,STK33,TEK,ZAP70 | 35 | |||
| kinase-selectivity-class | AXL,CAMK2D,CDK9,GRK2,IRAK1,MET,PRKDC,SIK2,TEK | 9 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 3.451 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 5.861 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 79.140 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 6.194 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 90.640 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 2.661 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 90.680 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 82.850 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 970.510 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 25, 2013 | FDA | TAKEDA PHARMS USA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pemphigoid | 110.29 | 26.17 | 29 | 2394 | 8997 | 90617027 |
| Cerebral infarction | 54.31 | 26.17 | 22 | 2401 | 26574 | 90599450 |
| Pancreatic carcinoma | 44.16 | 26.17 | 14 | 2409 | 8363 | 90617661 |
| Erythema multiforme | 38.95 | 26.17 | 14 | 2409 | 12232 | 90613792 |
| Diabetic ketoacidosis | 32.72 | 26.17 | 15 | 2408 | 24392 | 90601632 |
| Pancreatitis acute | 28.81 | 26.17 | 15 | 2408 | 32100 | 90593924 |
| Interstitial lung disease | 27.74 | 26.17 | 20 | 2403 | 76385 | 90549639 |
| Euglycaemic diabetic ketoacidosis | 27.13 | 26.17 | 9 | 2414 | 6192 | 90619832 |
| Hypoglycaemic encephalopathy | 26.55 | 26.17 | 5 | 2418 | 336 | 90625688 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pemphigoid | 210.41 | 21.89 | 64 | 3281 | 11403 | 42606587 |
| Pancreatitis | 77.55 | 21.89 | 46 | 3299 | 43222 | 42574768 |
| Cerebral infarction | 71.64 | 21.89 | 39 | 3306 | 31130 | 42586860 |
| Pancreatitis acute | 50.67 | 21.89 | 32 | 3313 | 33532 | 42584458 |
| Interstitial lung disease | 48.90 | 21.89 | 44 | 3301 | 78418 | 42539572 |
| Diabetic ketoacidosis | 45.92 | 21.89 | 26 | 3319 | 22341 | 42595649 |
| Tonsil cancer | 41.84 | 21.89 | 11 | 3334 | 1150 | 42616840 |
| Spondylolysis | 41.23 | 21.89 | 7 | 3338 | 84 | 42617906 |
| Lumbosacral radiculoplexus neuropathy | 34.35 | 21.89 | 6 | 3339 | 86 | 42617904 |
| Lactic acidosis | 33.45 | 21.89 | 28 | 3317 | 45233 | 42572757 |
| Gastric cancer | 32.10 | 21.89 | 14 | 3331 | 6889 | 42611101 |
| Application site haematoma | 30.28 | 21.89 | 5 | 3340 | 50 | 42617940 |
| Euglycaemic diabetic ketoacidosis | 28.02 | 21.89 | 12 | 3333 | 5648 | 42612342 |
| Angina pectoris | 27.78 | 21.89 | 22 | 3323 | 32874 | 42585116 |
| Appetite disorder | 27.69 | 21.89 | 10 | 3335 | 3005 | 42614985 |
| Hypoglycaemia | 26.76 | 21.89 | 28 | 3317 | 59826 | 42558164 |
| Drug-induced liver injury | 24.86 | 21.89 | 22 | 3323 | 38251 | 42579739 |
| Angioedema | 24.81 | 21.89 | 23 | 3322 | 42454 | 42575536 |
| Glycosylated haemoglobin increased | 23.79 | 21.89 | 14 | 3331 | 12910 | 42605080 |
| Hepatocellular carcinoma | 23.78 | 21.89 | 12 | 3333 | 8182 | 42609808 |
| Joint lock | 22.27 | 21.89 | 7 | 3338 | 1378 | 42616612 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pemphigoid | 325.42 | 21.13 | 93 | 5821 | 19614 | 110563771 |
| Cerebral infarction | 124.46 | 21.13 | 59 | 5855 | 51779 | 110531606 |
| Pancreatitis acute | 79.66 | 21.13 | 46 | 5868 | 60228 | 110523157 |
| Interstitial lung disease | 79.20 | 21.13 | 63 | 5851 | 139271 | 110444114 |
| Diabetic ketoacidosis | 77.50 | 21.13 | 40 | 5874 | 42018 | 110541367 |
| Pancreatitis | 77.30 | 21.13 | 53 | 5861 | 93480 | 110489905 |
| Euglycaemic diabetic ketoacidosis | 53.58 | 21.13 | 21 | 5893 | 11602 | 110571783 |
| Lactic acidosis | 52.78 | 21.13 | 42 | 5872 | 92769 | 110490616 |
| Pancreatic carcinoma | 48.57 | 21.13 | 21 | 5893 | 14851 | 110568534 |
| Hepatocellular carcinoma | 46.07 | 21.13 | 18 | 5896 | 9862 | 110573523 |
| Hypoglycaemia | 44.61 | 21.13 | 42 | 5872 | 116062 | 110467323 |
| Gastric cancer | 44.18 | 21.13 | 18 | 5896 | 10990 | 110572395 |
| Tonsil cancer | 39.72 | 21.13 | 10 | 5904 | 1296 | 110582089 |
| Erythema multiforme | 38.66 | 21.13 | 20 | 5894 | 21077 | 110562308 |
| Spondylolysis | 37.33 | 21.13 | 7 | 5907 | 226 | 110583159 |
| Lumbosacral radiculoplexus neuropathy | 34.91 | 21.13 | 6 | 5908 | 117 | 110583268 |
| Drug eruption | 32.03 | 21.13 | 25 | 5889 | 53634 | 110529751 |
| Hepatic function abnormal | 31.82 | 21.13 | 31 | 5883 | 89264 | 110494121 |
| Body temperature decreased | 30.65 | 21.13 | 21 | 5893 | 36914 | 110546471 |
| Application site haematoma | 30.14 | 21.13 | 5 | 5909 | 78 | 110583307 |
| Renal impairment | 29.56 | 21.13 | 43 | 5871 | 188402 | 110394983 |
| Cardiac failure | 28.25 | 21.13 | 42 | 5872 | 187584 | 110395801 |
| Blood glucose increased | 28.06 | 21.13 | 35 | 5879 | 132461 | 110450924 |
| Diabetes mellitus inadequate control | 27.27 | 21.13 | 18 | 5896 | 29757 | 110553628 |
| Angina pectoris | 26.76 | 21.13 | 24 | 5890 | 62271 | 110521114 |
| Glycosylated haemoglobin increased | 25.91 | 21.13 | 16 | 5898 | 23603 | 110559782 |
| Drug-induced liver injury | 25.87 | 21.13 | 32 | 5882 | 120035 | 110463350 |
| Colon cancer | 25.64 | 21.13 | 14 | 5900 | 16429 | 110566956 |
| Acute kidney injury | 25.31 | 21.13 | 83 | 5831 | 635347 | 109948038 |
| Altered state of consciousness | 24.36 | 21.13 | 22 | 5892 | 57604 | 110525781 |
| Angioedema | 24.09 | 21.13 | 28 | 5886 | 98472 | 110484913 |
| Hyperkalaemia | 22.77 | 21.13 | 32 | 5882 | 135764 | 110447621 |
| Diabetic nephropathy | 22.22 | 21.13 | 8 | 5906 | 3500 | 110579885 |
| Joint lock | 22.04 | 21.13 | 8 | 5906 | 3580 | 110579805 |
| Platelet count decreased | 21.90 | 21.13 | 42 | 5872 | 230401 | 110352984 |
| Constipation | 21.26 | 21.13 | 54 | 5860 | 357732 | 110225653 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BD09 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
| ATC | A10BD13 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
| ATC | A10BH04 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Dipeptidyl peptidase 4 (DPP-4) inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D007004 | Hypoglycemic Agents |
| MeSH PA | D011480 | Protease Inhibitors |
| MeSH PA | D054795 | Incretins |
| MeSH PA | D054873 | Dipeptidyl-Peptidase IV Inhibitors |
| FDA MoA | N0000175912 | Dipeptidyl Peptidase 4 Inhibitors |
| FDA EPC | N0000175913 | Dipeptidyl Peptidase 4 Inhibitor |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:68612 | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor |
Related Drugs by ATC class:
A10BD Combinations of oral blood glucose lowering drugs 19 drugs
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.4 | Basic |
| pKa2 | 1.33 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 12.5MG BASE | NESINA | TAKEDA PHARMS USA | N022271 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 25MG BASE | NESINA | TAKEDA PHARMS USA | N022271 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 6.25MG BASE | NESINA | TAKEDA PHARMS USA | N022271 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | DISCN | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 12.5MG BASE;EQ 30MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 12.5MG BASE;EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | DISCN | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 25MG BASE;EQ 15MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 25MG BASE;EQ 30MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 25MG BASE;EQ 45MG BASE | OSENI | TAKEDA PHARMS USA | N022426 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 12.5MG BASE;1GM | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| EQ 12.5MG BASE;500MG | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 12.5MG BASE | NESINA | TAKEDA PHARMS USA | N022271 | Jan. 25, 2013 | RX | TABLET | ORAL | July 27, 2026 | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST |
| EQ 25MG BASE | NESINA | TAKEDA PHARMS USA | N022271 | Jan. 25, 2013 | RX | TABLET | ORAL | July 27, 2026 | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST |
| EQ 6.25MG BASE | NESINA | TAKEDA PHARMS USA | N022271 | Jan. 25, 2013 | RX | TABLET | ORAL | July 27, 2026 | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST |
| EQ 12.5MG BASE;1GM | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | July 27, 2026 | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST |
| EQ 12.5MG BASE;500MG | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | July 27, 2026 | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Dipeptidyl peptidase 4 | Enzyme | INHIBITOR | IC50 | 9 | CHEMBL | CHEMBL | |||
| Dipeptidyl peptidase 4 | Enzyme | IC50 | 8.07 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4032098 | VUID |
| N0000186570 | NUI |
| D06553 | KEGG_DRUG |
| 4032097 | VANDF |
| 4032098 | VANDF |
| C1958126 | UMLSCUI |
| CHEBI:72323 | CHEBI |
| T22 | PDB_CHEM_ID |
| CHEMBL376359 | ChEMBL_ID |
| CHEMBL227529 | ChEMBL_ID |
| DB06203 | DRUGBANK_ID |
| C520853 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6319 | IUPHAR_LIGAND_ID |
| 8814 | INN_ID |
| 850649-62-6 | SECONDARY_CAS_RN |
| JHC049LO86 | UNII |
| 11450633 | PUBCHEM_CID |
| 1368000 | RXNORM |
| 198438 | MMSL |
| 237036 | MMSL |
| 29087 | MMSL |
| 399893 | MMSL |
| d07963 | MMSL |
| 014872 | NDDF |
| 014873 | NDDF |
| 702799001 | SNOMEDCT_US |
| 702800002 | SNOMEDCT_US |
| 703669009 | SNOMEDCT_US |
| JHC049LO86 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Alogliptin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-087 | TABLET, FILM COATED | 6.25 mg | ORAL | NDA authorized generic | 28 sections |
| Alogliptin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-103 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA authorized generic | 28 sections |
| Alogliptin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-150 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 28 sections |
| alogliptin and metformin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-169 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA authorized generic | 29 sections |
| alogliptin and metformin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-211 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA authorized generic | 29 sections |
| Alogliptin and Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-260 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA authorized generic | 31 sections |
| Alogliptin and Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-351 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 31 sections |
| Alogliptin and Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-402 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 31 sections |
| Alogliptin and Pioglitazone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-499 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 31 sections |
| Alogliptin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5574 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 27 sections |
| alogliptin and metformin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-5993 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA authorized generic | 28 sections |
| Alogliptin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-4946 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 27 sections |
| OSENI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64764-123 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA | 32 sections |
| Nesina | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-125 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA | 31 sections |
| Nesina | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-250 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 31 sections |
| OSENI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64764-251 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 32 sections |
| OSENI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64764-253 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 32 sections |
| OSENI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64764-254 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 32 sections |
| KAZANO | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64764-335 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA | 30 sections |
| KAZANO | HUMAN PRESCRIPTION DRUG LABEL | 2 | 64764-337 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA | 30 sections |
| Nesina | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-625 | TABLET, FILM COATED | 6.25 mg | ORAL | NDA | 31 sections |
| Alogliptin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71610-300 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 28 sections |
| Alogliptin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71610-661 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA authorized generic | 28 sections |